research Alopecia areata during Interferon Alpha-2b/Ribavirin Therapy
This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.
Search
for
Did you mean Interferon-alpha?
Sort by
Research
30 / 1000+ results research Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C
This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.
research Interferon alpha 2B
Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.
research Clinical Characteristics and Factors Associated with Hair Loss Severity in Chronic Hepatitis B Patients Receiving Pegylated Interferon-Alpha: A Retrospective Cohort Study
In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.
research A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma
This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.
research Tumour Necrosis Factor Alpha, Interferon Gamma and Substance P Are Novel Modulators of Extrapituitary Prolactin Expression in Human Skin
This study identifies substance P, TNFα, and IFNγ as novel regulators of prolactin and its receptor expression in human skin, suggesting intracutaneous prolactin is not controlled by dopamine.
research Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV
This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.
research Bullous Lesions at Polyethylene Glycol Interferon-alpha-2a Inoculation Site in a Hepatitis C Virus-infected Subject
In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.
research Segmental Vitiligo and Hair Curling After Interferon α and Ribavirin Treatment for Hepatitis C
A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.
research The influence of interferon on healthy and diseased skin
This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
research Alopesi areata hastalarında serum interferon-gama, tümör nekrozis faktör-alfa, interlökin-13, interlökin-17 ve transforming growth faktör-beta düzeylerinin değerlendirilmesi
In this study, serum IL-13 and TGF-β concentrations were significantly different between alopecia areata patients and controls, suggesting a role for these cytokines in the disease's pathogenesis.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.
research Current management strategies for cutaneous T-cell lymphoma
This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.
research Skin diseases associated with hepatitis C virus: Facts and controversies
This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.
research Intralesional therapy for the treatment of keratoacanthoma
This study reviewed the current state of intralesional therapy for keratoacanthoma, finding that while methotrexate, 5-fluorouracil, and interferon alpha are common agents, guidelines are still needed, and histopathological confirmation is advised to prevent misdiagnosis with squamous cell carcinoma.
research Treatments for alopecia areata: A systematic review and network meta‐analysis
This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.
research Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
This review discusses zinc supplementation as a complementary therapy for chronic hepatitis C, noting its potential benefits in improving treatment outcomes and reducing side effects, but reports no new clinical results.
research Case Report: Diffuse Hypertrichosis in the Course of Hepatitis C Treatment by IFN-α and Ribavirin
In this case study, hypertrichosis in a patient with hemophilia and hepatitis C may have been induced by IFN-alpha treatment, despite the drug usually causing hair loss.
research Immunomodulators in the treatment of cutaneous lymphoma
This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.
research Hepatitis C Treatment and Alopecia Totalis
This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.
research Reply
The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.
research Widespread Dystrophic-Anagen Alopecia and Drug Eruption due to Usage of PEG-IFN ?-2a /Ribavirin Combination Therapy
This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.
research Plasmacytoid dendritic cells as a key player in the initiation phase of alopecia areata-induced C3H/HeJ mouse
This study found that plasmacytoid dendritic cells may initiate alopecia areata in mice by overexpressing interferon-alpha.
research THERAPEUTIC CHALLENGES IN POLYAUTOIMMUNITY: ANIFROLUMAB FOR LUPUS ERYTHEMATODES IN OVERLAPPING AUTOIMMUNE SYNDROMES
In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.
research Resolution of advanced conjunctival squamous cell carcinoma with cemiplimab immunotherapy, IFNα-2b, and retinoic acid treatment over 2 years of follow-up
The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.
research Correspondence
A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.
research Dermatologic therapy: December 1986 to December 1987
This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.